Sequence of DHI2_HUMAN

11beta-hydroxysteroid dehydrogenase (NAD+)

P80365

405

44127

11beta-hydroxysteroid dehydrogenase

P80365

405

44127

1049964

Albiston A.L.,Obeyesekere V.R.,Smith R.E.,Krozowski Z.S.

Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme.

Mol. Cell. Endocrinol.

105

0-0

1994

1049965

Agarwal A.K.,Rogerson F.M.,Mune T.,White P.C.

Gene structure and chromosomal localization of the human HSD11K gene encoding the kidney (type 2) isozyme of 11 beta-hydroxysteroid dehydrogenase.

Genomics

29

195-199

1995

1049966

Brown R.W.,Chapman K.E.,Kotelevtsev Y.,Yau J.L.,Lindsay R.S.,Brett L.,Leckie C.,Murad P.,Lyons V.,Mullins J.J.,Edwards C.R.W.,Seckl J.R.

Cloning and production of antisera to human placental 11 beta-hydroxysteroid dehydrogenase type 2.

Biochem. J.

313

1007-1017

1996

1049970

The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).

Genome Res.

14

2121-2127

2004

1049971

Brown R.W.,Chapman K.E.,Murad P.,Edwards C.R.,Seckl J.R.

Purification of 11 beta-hydroxysteroid dehydrogenase type 2 from human placenta utilizing a novel affinity labelling technique.

Biochem. J.

313

997-1005

1996

1049973

Wilson R.C.,Harbison M.D.,Krozowski Z.S.,Funder J.W.,Shackleton C.H.L.,Hanauske-Abel H.M.,Wei J.-Q.,Hertecant J.,Moran A.,Neiberger R.E.,Balfe J.W.,Fattah A.,Daneman D.,Licholai T.,New M.I.

Several homozygous mutations in the gene for 11 beta-hydroxysteroid dehydrogenase type 2 in patients with apparent mineralocorticoid excess.

J. Clin. Endocrinol. Metab.

80

3145-3150

1995

1049974

Stewart P.M.,Krozowski Z.S.,Gupta A.,Milford D.V.,Howie A.J.,Sheppard M.C.,Whorwood C.B.

Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11 beta-hydroxysteroid dehydrogenase type 2 gene.

Lancet

347

88-91

1996

1049975

Stewart P.M.,Wallace A.M.,Valentino R.,Burt D.,Shackleton C.H.L.,Edwards C.R.W.

Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age.

Lancet

2

821-824

1987

1049976

Odermatt A.,Arnold P.,Stauffer A.,Frey B.M.,Frey F.J.

The N-terminal anchor sequences of 11beta-hydroxysteroid dehydrogenases determine their orientation in the endoplasmic reticulum membrane.

J. Biol. Chem.

274

28762-28770

1999

1049977

Odermatt A.,Arnold P.,Frey F.J.

The intracellular localization of the mineralocorticoid receptor is regulated by 11beta-hydroxysteroid dehydrogenase type 2.

J. Biol. Chem.

276

28484-28492

2001

1049978

Meyer A.,Strajhar P.,Murer C.,Da Cunha T.,Odermatt A.

Species-specific differences in the inhibition of human and zebrafish 11beta-hydroxysteroid dehydrogenase 2 by thiram and organotins.

Toxicology

301

72-78

2012

1049979

Tsachaki M.,Meyer A.,Weger B.,Kratschmar D.V.,Tokarz J.,Adamski J.,Belting H.G.,Affolter M.,Dickmeis T.,Odermatt A.

Absence of 11-keto reduction of cortisone and 11-ketotestosterone in the model organism zebrafish.

J. Endocrinol.

232

323-335

2017

1049980

Beck K.R.,Kanagaratnam S.,Kratschmar D.V.,Birk J.,Yamaguchi H.,Sailer A.W.,Seuwen K.,Odermatt A.

Enzymatic interconversion of the oxysterols 7beta,25-dihydroxycholesterol and 7-keto,25-hydroxycholesterol by 11beta-hydroxysteroid dehydrogenase type 1 and 2.

J. Steroid Biochem. Mol. Biol.

190

19-28

2019

1049981

Inderbinen S.G.,Zogg M.,Kley M.,Smiesko M.,Odermatt A.

Species-specific differences in the inhibition of 11beta-hydroxysteroid dehydrogenase 2 by itraconazole and posaconazole.

Toxicol. Appl. Pharmacol.

412

115387-115387

2021

1049982

Wilson R.C.,Krozowski Z.S.,Li K.,Obeyesekere V.R.,Razzaghy-Azar M.,Harbison M.D.,Wei J.-Q.,Shackleton C.H.L.,Funder J.W.,New M.I.

A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess.

J. Clin. Endocrinol. Metab.

80

2263-2266

1995

1049983

Mune T.,Rogerson F.M.,Nikkilae H.,Agarwal A.K.,White P.C.

Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase.

Nat. Genet.

10

394-399

1995

1049984

Kitanaka S.,Katsumata N.,Tanae A.,Hibi I.,Takeyama K.,Fuse H.,Kato S.,Tanaka T.

A new compound heterozygous mutation in the 11 beta-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess.

J. Clin. Endocrinol. Metab.

82

4054-4058

1997

1049985

Li A.,Tedde R.,Krozowski Z.S.,Pala A.,Li K.X.Z.,Shackleton C.H.L.,Mantero F.,Palermo M.,Stewart P.M.

Molecular basis for hypertension in the 'type II variant' of apparent mineralocorticoid excess.

Am. J. Hum. Genet.

63

370-379

1998

1049986

Dave-Sharma S.,Wilson R.C.,Harbison M.D.,Newfield R.,Azar M.R.,Krozowski Z.S.,Funder J.W.,Shackleton C.H.L.,Bradlow H.L.,Wei J.-Q.,Hertecant J.,Moran A.,Neiberger R.E.,Balfe J.W.,Fattah A.,Daneman D.,Akkurt H.I.,De Santis C.,New M.I.

Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess.

J. Clin. Endocrinol. Metab.

83

2244-2254

1998

1049987

Rogoff D.,Smolenicka Z.,Bergada I.,Vallejo G.,Barontini M.,Heinrich J.J.,Ferrari P.

The codon 213 of the 11beta-hydroxysteroid dehydrogenase type 2 gene is a hot spot for mutations in apparent mineralocorticoid excess.

J. Clin. Endocrinol. Metab.

83

4391-4393

1998

1049988

Wilson R.C.,Dave-Sharma S.,Wei J.-Q.,Obeyesekere V.R.,Li K.,Ferrari P.,Krozowski Z.S.,Shackleton C.H.L.,Bradlow L.,Wiens T.,New M.I.

A genetic defect resulting in mild low-renin hypertension.

Proc. Natl. Acad. Sci. U.S.A.

95

10200-10205

1998

1049989

Morineau G.,Marc J.-M.,Boudi A.,Galons H.,Gourmelen M.,Corvol P.,Pascoe L.,Fiet J.

Genetic, biochemical, and clinical studies of patients with A328V or R213C mutations in 11betaHSD2 causing apparent mineralocorticoid excess.

Hypertension

34

435-441

1999

1049990

Nunez B.S.,Rogerson F.M.,Mune T.,Igarashi Y.,Nakagawa Y.,Phillipov G.,Moudgil A.,Travis L.B.,Palermo M.,Shackleton C.H.L.,White P.C.

Mutants of 11beta-hydroxysteroid dehydrogenase (11-HSD2) with partial activity: improved correlations between genotype and biochemical phenotype in apparent mineralocorticoid excess.

Hypertension

34

638-642

1999

1049991

Odermatt A.,Dick B.,Arnold P.,Zaehner T.,Plueschke V.,Deregibus M.N.,Repetto H.,Frey B.M.,Frey F.J.,Ferrari P.

A mutation in the cofactor-binding domain of 11beta-hydroxysteroid dehydrogenase type 2 associated with mineralocorticoid hypertension.

J. Clin. Endocrinol. Metab.

86

1247-1252

2001

1049992

Carvajal C.A.,Gonzalez A.A.,Romero D.G.,Gonzalez A.,Mosso L.M.,Lagos E.T.,Hevia Mdel P.,Rosati M.P.,Perez-Acle T.O.,Gomez-Sanchez C.E.,Montero J.A.,Fardella C.E.

Two homozygous mutations in the 11 beta-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess.

J. Clin. Endocrinol. Metab.

88

2501-2507

2003

1049993

Atanasov A.G.,Ignatova I.D.,Nashev L.G.,Dick B.,Ferrari P.,Frey F.J.,Odermatt A.

Impaired protein stability of 11beta-hydroxysteroid dehydrogenase type 2: a novel mechanism of apparent mineralocorticoid excess.

J. Am. Soc. Nephrol.

18

1262-1270

2007